Abstract
Background Sub-Saharan Africa (SSA) has the highest prevalence of cardiovascular diseases (CVD). Nevertheless, very few studies have directly examined the development of and risk factors for CVD among Africans.
Objective To examine CVD risk factors and outcomes particularly in the early stage of CVD development among adults in Ghana.
Methods Using a stratified multistage random sampling method, 1,106 participants were recruited as a nationally representative sample of the general population ≥18 years in Ghana from 2016 to 2017. For each participant, we measured CVD risk factors and preclinical target organ damage (TOD) for CVD development.
Results The prevalence of CVD risk factors was 21.1% for obesity, 10.8% for diabetes, 55.4% for hypertension, 37.3% for dyslipidemia, 12.8% for hyperuricemia, and 39.3% for hsCRP>3 mg/L in the recruited population. The prevalence of preclinical TOD was 8.6% for peripheral artery disease (PAD), 14.7% for carotid thickening, 5.9% for left ventricular hypertrophy (LVH), and 4.4% for chronic kidney disease (CKD). Three CVD risk factors appeared to play most prominent roles in TOD development, including obesity for PAD (OR 1.88, 95% CI 1.13–3.09), hypertension for carotid thickening (OR 1.57, 95% CI 0.99–2.54) and LVH (OR 6.25, 95% CI 2.98–14.50), and hyperuricemia for CKD (OR 5.56, 95% CI 2.79–11.15).
Conclusions The prevalence of CVD risk factors and early outcomes have reached epidemic proportions among Ghanaian adults. The distinct patterns of risk factors in the development of TOD presents important challenges and opportunities for interventions to improve cardiometabolic health among adults in Ghana.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by China-Ghana West African Heart Center Cooperation Project (to CL) funded by the National Health Commission of People’s Republic of China. SL was partially funded by the U.S. Fulbright Scholar Program.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding This study was supported by China-Ghana West African Heart Center Cooperation Project (to CL) funded by the National Health Commission of People’s Republic of China. SL was partially funded by the U.S. Fulbright Scholar Program.
Disclosures: None.
Acknowledgements The authors would like to express their sincere gratitude to all the participants who were involved in this study, and the research assistants for the support they provided. Without their co-operation this study would not have been successful.
Data Availability
The data can be available by contacting the corresponding authors.
